Complement Anaphylatoxin Receptors in Inflammation

补充炎症中的过敏毒素受体

基本信息

项目摘要

DESCRIPTION (provided by applicant): One of the major biological consequences of complement activation is the generation of three small cationic peptides C3a, C4a, and C5a, collectively referred to as complement anaphylatoxins. The complement anaphylatoxins are potent proinflammatory molecules that mediate numerous biological functions by binding to seven transmembrane G-protein coupled receptors expressed on specific target cells. The acute and chronic overproduction of complement anaphylatoxin peptides is considered to be a major contributor to the pathogenesis of numerous diseases, including rheumatoid arthritis, psoriasis, septic shock, myocardial ischemic injury, acute respiratory distress syndrome, and multiple system organ failure. The goal of this research program is to increase our understanding of the specific and overall roles that complement anaphylatoxin peptides and their receptors play in inflammation and immunity. During the next several years, the cellular expression and biological functions mediated by the C3a receptor will be examined in detail. In addition, the in vivo biological role of the C3a receptor will be studied and evaluated using a C3a receptor "knock-out" mouse in several well-characterized models of inflammation, infection, and autoimmunity. These studies will be accomplished by four major specific aims: 1) to determine the cells in peripheral blood and selected tissues that express the C3a anaphylatoxin receptor, and to delineate C3a mediated biological functions by cells expressing the C3a receptor, 2) to determine the effect of C3a receptor deficiency on pulmonary inflammation in established models of immune-complex injury, asthma, and bacterial infection and clearance, 3) to determine the effect of C3a receptor deficiency in the skin using established models of infectious dermatitis, immune-complex injury, and bullous pemphigoid, and 4) to determine the effect of C3a receptor deficiency in the peritoneum using established models of immune-complex peritonitis, acute septic peritonitis, and septic shock.
描述(由申请人提供):主要生物学后果之一 补体激活的关键是产生三种小的阳离子肽 C3a、C4a和C5a,统称为补体过敏毒素。的 补体过敏毒素是有效的促炎分子, 通过与七跨膜G蛋白结合而具有多种生物学功能 偶联受体表达的特定靶细胞。急性和慢性 补体过敏毒素肽的过度产生被认为是 促进许多疾病的发病机制,包括类风湿性关节炎 关节炎,银屑病,感染性休克,心肌缺血性损伤,急性 呼吸窘迫综合征和多系统器官衰竭。的目标 这项研究计划是为了增加我们对特定的, 补充过敏毒素肽及其受体的总体作用 在炎症和免疫方面。在接下来的几年里, C3a受体介导的表达和生物学功能将被 详细检查。此外,C3 a的体内生物学作用 将使用C3a受体“敲除”小鼠研究和评价C3a受体 在几种充分表征的炎症、感染和 自身免疫这些研究将通过四个主要具体目标来完成: 1)以确定外周血和选定组织中表达 C3a过敏毒素受体,并描绘C3a介导的生物学特性 通过表达C3a受体的细胞发挥功能,2)确定 C3 a受体缺陷对已建立的肺炎症模型的影响 免疫复合物损伤、哮喘、细菌感染和清除,3) 确定C3a受体缺乏症在皮肤中的影响, 感染性皮炎、免疫复合物损伤和大疱性类天疱疮模型, (4)确定腹膜中C3a受体缺陷的影响 使用已建立的免疫复合物腹膜炎、急性脓毒性 腹膜炎和感染性休克

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICK A. WETSEL其他文献

RICK A. WETSEL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICK A. WETSEL', 18)}}的其他基金

Cross-Regulation of Atherosclerosis and Autoimmunity
动脉粥样硬化和自身免疫的交叉调节
  • 批准号:
    8761633
  • 财政年份:
    2014
  • 资助金额:
    $ 29.75万
  • 项目类别:
Cross-Regulation of Atherosclerosis and Autoimmunity
动脉粥样硬化和自身免疫的交叉调节
  • 批准号:
    8891486
  • 财政年份:
    2014
  • 资助金额:
    $ 29.75万
  • 项目类别:
Mouse C4b-binding Protein in Adaptive Immunity
适应性免疫中的小鼠 C4b 结合蛋白
  • 批准号:
    7426383
  • 财政年份:
    2006
  • 资助金额:
    $ 29.75万
  • 项目类别:
Mouse C4b-binding Protein in Adaptive Immunity
适应性免疫中的小鼠 C4b 结合蛋白
  • 批准号:
    7076292
  • 财政年份:
    2006
  • 资助金额:
    $ 29.75万
  • 项目类别:
Complement in Allergic Lung Disease
过敏性肺病的补体
  • 批准号:
    7092054
  • 财政年份:
    2003
  • 资助金额:
    $ 29.75万
  • 项目类别:
Complement in Allergic Lung Disease
过敏性肺病的补体
  • 批准号:
    6919146
  • 财政年份:
    2003
  • 资助金额:
    $ 29.75万
  • 项目类别:
Complement in Allergic Lung Disease
过敏性肺病的补体
  • 批准号:
    6677234
  • 财政年份:
    2003
  • 资助金额:
    $ 29.75万
  • 项目类别:
Complement in Allergic Lung Disease
过敏性肺病的补体
  • 批准号:
    6772516
  • 财政年份:
    2003
  • 资助金额:
    $ 29.75万
  • 项目类别:
COMPLEMENT C5 DEFICIENCY--MOLECULAR ANALYSIS
补充C5缺乏症--分子分析
  • 批准号:
    3070955
  • 财政年份:
    1989
  • 资助金额:
    $ 29.75万
  • 项目类别:
COMPLEMENT C5 DEFICIENCY--MOLECULAR ANALYSIS
补充C5缺乏症--分子分析
  • 批准号:
    3070957
  • 财政年份:
    1989
  • 资助金额:
    $ 29.75万
  • 项目类别:

相似国自然基金

Complement C6蛋白抑制DNA损伤修复增敏甲状腺乳头状癌放射性碘治疗的作用及其机制
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Investigating the role of complement component 5a in ANCA-associated vasculitis
研究补体成分 5a 在 ANCA 相关血管炎中的作用
  • 批准号:
    MR/Y000854/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.75万
  • 项目类别:
    Fellowship
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
  • 批准号:
    10751872
  • 财政年份:
    2024
  • 资助金额:
    $ 29.75万
  • 项目类别:
NSF Convergence Accelerator, Track M: TANDEM: Tensegrity-based Assistive aND rehabilitation Exosuits to complement human bioMechanics
NSF 融合加速器,轨道 M:TANDEM:基于张拉整体的辅助和康复外装,以补充人体生物力学
  • 批准号:
    2344385
  • 财政年份:
    2024
  • 资助金额:
    $ 29.75万
  • 项目类别:
    Standard Grant
Development of a novel oral vaccine for fish: Synergy of chitosan nano particle and complement-mediated opsonization
新型鱼类口服疫苗的开发:壳聚糖纳米颗粒与补体介导的调理作用的协同作用
  • 批准号:
    24K17960
  • 财政年份:
    2024
  • 资助金额:
    $ 29.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Crosstalk between purinergic signaling and the complement system in sepsis-induced immunosuppression.
脓毒症引起的免疫抑制中嘌呤能信号传导与补体系统之间的串扰。
  • 批准号:
    23H03013
  • 财政年份:
    2023
  • 资助金额:
    $ 29.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Complement Protein C1q Regulation of Macrophage Metabolic Pathways
补体蛋白 C1q 对巨噬细胞代谢途径的调节
  • 批准号:
    10629550
  • 财政年份:
    2023
  • 资助金额:
    $ 29.75万
  • 项目类别:
Lung-derived complement in pneumonia
肺炎中的肺源性补体
  • 批准号:
    10568567
  • 财政年份:
    2023
  • 资助金额:
    $ 29.75万
  • 项目类别:
Complement Resistance Acquired During Acute to Persistent Rubulavirus Infection
急性至持续性风疹病毒感染期间获得的补体耐药性
  • 批准号:
    10645486
  • 财政年份:
    2023
  • 资助金额:
    $ 29.75万
  • 项目类别:
Defining the impact of complement inhibition by tick saliva in tick-borne virus evolution and adaptive immune responses in murine models of infection
定义蜱唾液抑制补体对蜱传病毒进化和小鼠感染模型适应性免疫反应的影响
  • 批准号:
    10535945
  • 财政年份:
    2023
  • 资助金额:
    $ 29.75万
  • 项目类别:
Inhibition of Complement Pathways with VCP As A Treatment For Alzheimer's Disease
VCP 抑制补体途径治疗阿尔茨海默病
  • 批准号:
    10602757
  • 财政年份:
    2023
  • 资助金额:
    $ 29.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了